NuVasive Inc.
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. it provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology and its intraoperative neuromonitoring services and support; and specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone. The company also offers reline fixation system that facilitates the preservation and restoration of patient alignment; integrated global alignment platform consisting of Bendini spinal rod bending system that assists with manual rod manipulation for spinal fixation; Lessray that is an image enhancement platform designed to reduce radiation exposure in the operating room, as well as Pulse, which integrates multiple enabling technologies to enhance workflow, reduce variability, and increase the reproducibility of surgical outcomes; and various biologics that are used to aid in the spinal fusion or bone healing process. In addition, it provides MAGEC, a spinal bracing and distraction system, Precice limb lengthening system, and various other products for treating specialized orthopedic procedures; onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries; and cervical artificial disc technology for cervical total disc replacement procedures. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
IPO Year: 2004
Exchange: NASDAQ
Website: nuvasive.com
Peers
Recent Analyst Ratings for NuVasive Inc.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/10/2023 | $57.72 | Overweight → Equal Weight | Wells Fargo |
| 2/10/2023 | $63.00 → $52.00 | Buy → Neutral | Citigroup |
| 2/10/2023 | $51.00 → $52.50 | Buy → Hold | Truist |
| 1/6/2023 | Buy → Hold | Needham | |
| 10/18/2022 | $53.00 | Overweight | Barclays |
| 10/12/2022 | $45.00 | Hold | Jefferies |
| 4/13/2022 | $60.00 → $65.00 | Buy | Truist |
| 3/28/2022 | $58.00 | Overweight | Wells Fargo |
| 1/7/2022 | $62.00 → $60.00 | Equal-Weight | Morgan Stanley |
| 12/21/2021 | $75.00 → $60.00 | Buy | Truist Securities |
NuVasive Inc. Press Releases
Fastest customizable press release news feed in the world
NuVasive to Participate as Double Diamond Sponsor at Scoliosis Research Society Annual Meeting
SAN DIEGO, Aug. 30, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will continue its partnership with the Scoliosis Research Society (SRS) as a double diamond sponsor and will attend the 58th Annual Meeting held September 6-9, 2023, in Seattle. "We partner with esteemed societies like SRS because of our shared dedication to clinical research, education, and thought leadership around advancing patient care, especi
Goosehead Insurance and Jackson Financial Set to Join S&P SmallCap 600
NEW YORK, Aug. 28, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 1: Goosehead Insurance Inc. (NASD: GSHD) will replace NuVasive Inc. (NASD: NUVA) in the S&P SmallCap 600. S&P MidCap 400 constituent Globus Medical Inc. (NYSE:GMED) is acquiring NuVasive in a deal expected to close soon pending final conditions.Jackson Financial Inc. (NYSE:JXN) will replace NexTier Oilfield Solutions Inc. (NYSE:NEX) in the S&P SmallCap 600. S&P SmallCap 600 constituent Patterson-UTI Energy Inc. (NASD: PTEN) is acquiring NexTier Oilfield Solutions in a deal expected to close soon pending final cond
NuVasive Announces Second Quarter 2023 Financial Results
–U.S. Cervical continues to deliver greater than 20% year-over-year growth––International net sales grew 6.8% as reported and 9.8% on a constant currency basis– SAN DIEGO, Aug. 2, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2023. Second Quarter 2023 Highlights Net sales were $317.8 million, a 2.4% increase as reported and a 3.1% increase on a constant currency basi
NuVasive Announces Conference Call and Webcast of Second Quarter 2023 Results
SAN DIEGO, July 24, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that it will release its second quarter 2023 results on Wednesday, August 2, 2023, after the close of the market. NuVasive will hold a conference call on Wednesday, August 2, 2023, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results of its financial performance for the second quarter of 2023. The dial-in numbers are 1-877-407-9039 for domestic calle
NuVasive Announces First Quarter 2023 Financial Results
–Continued above-market worldwide net sales growth of 5.8% as reported and 7.7% on a constant currency basis––U.S. cervical delivers sixth consecutive quarter of greater than 20% growth, driven by C360 and the Simplify Cervical Disc– SAN DIEGO, May 10, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended March 31, 2023. First Quarter 2023 Highlights Net sales were $307.7 million, a
NuVasive Announces Conference Call and Webcast of First Quarter 2023 Results
SAN DIEGO, May 4, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its first quarter 2023 results on Wednesday, May 10, 2023, after the close of the market. NuVasive will hold a conference call on Wednesday, May 10, 2023, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results of its financial performance for the first quarter of 2023. The dial-in numbers are 1-877-300-8521 for domestic callers a
Globus Medical Shareholders Approve Share Issuance for Merger with NuVasive
AUDUBON, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that at the special meeting of shareholders held earlier today its shareholders voted to approve the issuance of shares of Globus Medical Class A common stock in connection with the proposed merger with NuVasive (NASDAQ:NUVA). As previously announced, under the terms of the merger agreement, Globus Medical will issue 0.75 of a share of Globus Medical Class A common stock in exchange for each share of NuVasive common stock owned at the closing of the transaction. "Globus Medical shareholders showed an overwhelming level of support for this merger,"
NuVasive Shareholders Approve Merger Agreement with Globus Medical
SAN DIEGO, April 27, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced that at the special meeting of shareholders held earlier today, its shareholders voted to approve the adoption of the Company's merger agreement with Globus Medical (NYSE:GMED). As previously announced, under the terms of the merger agreement, NuVasive shareholders will receive 0.75 of a share of Globus Medical Class A common stock for each share of NuVasive common stock owned at the closing of the transaction.
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending NuVasive Shareholders Vote "FOR" the Proposed Merger with Globus Medical
SAN DIEGO, April 17, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced that proxy advisory firm, Glass Lewis & Co., LLC ("Glass Lewis"), recommends that NuVasive shareholders vote "FOR" the shareholder proposal to adopt the merger agreement with Globus Medical (NYSE:GMED) at NuVasive's upcoming special meeting of shareholders ("the special meeting") scheduled for April 27, 2023. Only holders of record of NuVasive common stock as of the close of business on March 24, 2023, are entitled to vote at the special meeting.
Leading Independent Proxy Advisory Firm ISS Recommends NuVasive Shareholders Vote "FOR" the Proposed Merger with Globus Medical
SAN DIEGO, April 14, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced that leading independent proxy advisory firm Institutional Shareholder Services ("ISS") recommends that NuVasive shareholders vote "FOR" the shareholder proposal to adopt the merger agreement with Globus Medical (NYSE:GMED) at NuVasive's upcoming special meeting of shareholders ("the special meeting") scheduled for April 27, 2023. Only holders of record of NuVasive common stock as of the close of business on March 24, 2023 are entitled to vote at the special meetin
NuVasive Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
NuVasive downgraded by Wells Fargo with a new price target
Wells Fargo downgraded NuVasive from Overweight to Equal Weight and set a new price target of $57.72
NuVasive downgraded by Citigroup with a new price target
Citigroup downgraded NuVasive from Buy to Neutral and set a new price target of $52.00 from $63.00 previously
NuVasive downgraded by Truist with a new price target
Truist downgraded NuVasive from Buy to Hold and set a new price target of $52.50 from $51.00 previously
NuVasive downgraded by Needham
Needham downgraded NuVasive from Buy to Hold
Barclays initiated coverage on NuVasive with a new price target
Barclays initiated coverage of NuVasive with a rating of Overweight and set a new price target of $53.00
Jefferies initiated coverage on NuVasive with a new price target
Jefferies initiated coverage of NuVasive with a rating of Hold and set a new price target of $45.00
Truist resumed coverage on NuVasive with a new price target
Truist resumed coverage of NuVasive with a rating of Buy and set a new price target of $65.00 from $60.00 previously
Wells Fargo initiated coverage on NuVasive with a new price target
Wells Fargo initiated coverage of NuVasive with a rating of Overweight and set a new price target of $58.00
Morgan Stanley reiterated coverage on NuVasive with a new price target
Morgan Stanley reiterated coverage of NuVasive with a rating of Equal-Weight and set a new price target of $60.00 from $62.00 previously
Truist Securities reiterated coverage on NuVasive with a new price target
Truist Securities reiterated coverage of NuVasive with a rating of Buy and set a new price target of $60.00 from $75.00 previously
NuVasive Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
SEC Form 4 filed by Wolterman Dan
4 - NUVASIVE INC (0001142596) (Issuer)
SEC Form 4 filed by Raimundo Amy Belt
4 - NUVASIVE INC (0001142596) (Issuer)
SEC Form 4: Norwalk Leslie V returned 3,095 shares to the company, closing all direct ownership in the company
4 - NUVASIVE INC (0001142596) (Issuer)
SEC Form 4: Kadia Siddhartha returned 3,739 shares to the company, closing all direct ownership in the company
4 - NUVASIVE INC (0001142596) (Issuer)
SEC Form 4: Huennekens R Scott returned 1,360 shares to the company, closing all direct ownership in the company
4 - NUVASIVE INC (0001142596) (Issuer)
SEC Form 4 filed by Friel Robert F
4 - NUVASIVE INC (0001142596) (Issuer)
SEC Form 4 filed by Deford John A
4 - NUVASIVE INC (0001142596) (Issuer)
SEC Form 4: Capps Vickie L returned 2,000 shares to the company, closing all direct ownership in the company
4 - NUVASIVE INC (0001142596) (Issuer)
SEC Form 4: Wolf Dale A. returned 8,943 shares to the company, closing all direct ownership in the company
4 - NUVASIVE INC (0001142596) (Issuer)
SEC Form 4: Sisitsky Nathaniel returned 22,423 shares to the company, closing all direct ownership in the company
4 - NUVASIVE INC (0001142596) (Issuer)
NuVasive Inc. SEC Filings
SEC Form 15-12G filed by NuVasive Inc.
15-12G - NUVASIVE INC (0001142596) (Filer)
SEC Form EFFECT filed by NuVasive Inc.
EFFECT - NUVASIVE INC (0001142596) (Filer)
SEC Form EFFECT filed by NuVasive Inc.
EFFECT - NUVASIVE INC (0001142596) (Filer)
SEC Form EFFECT filed by NuVasive Inc.
EFFECT - NUVASIVE INC (0001142596) (Filer)
SEC Form EFFECT filed by NuVasive Inc.
EFFECT - NUVASIVE INC (0001142596) (Filer)
SEC Form EFFECT filed by NuVasive Inc.
EFFECT - NUVASIVE INC (0001142596) (Filer)
SEC Form EFFECT filed by NuVasive Inc.
EFFECT - NUVASIVE INC (0001142596) (Filer)
SEC Form S-8 POS filed by NuVasive Inc.
S-8 POS - NUVASIVE INC (0001142596) (Filer)
SEC Form S-8 POS filed by NuVasive Inc.
S-8 POS - NUVASIVE INC (0001142596) (Filer)
SEC Form S-8 POS filed by NuVasive Inc.
S-8 POS - NUVASIVE INC (0001142596) (Filer)
NuVasive Inc. Leadership Updates
Live Leadership Updates
BrightInsight Adds Medical Device and Biopharmaceutical Experts, Tamara Elias, M.D., and Scott Huennekens to Advisory Council
SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek
Blue Spark Technologies Announces Appointment of John DeFord, Ph.D. to its Board of Directors
The new board member will provide extensive expertise to expand the TempTraq® remote patient monitoring platform Blue Spark Technologies Inc., a leader in wearable remote patient monitoring solutions, announced today the appointment of John DeFord, Ph.D. to its board of directors. Dr. DeFord's appointment, effective April 13th, 2022, brings the number of board members to five. "This is really an inflection point for the company and it's an exciting time to be involved. I look forward to helping mold the future of their technology," said Dr. DeFord. "I'm particularly excited to see the technology come together that will make an impact in patient's lives." "We are proud to welcome John to
NuVasive Appoints Andrew C. Morton as Chief Human Resources Officer
SAN DIEGO, Jan. 31, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the appointment of Andrew (Drew) C. Morton as senior vice president and chief human resources officer (CHRO) effective February 7, 2022. Mr. Morton brings more than 25 years of experience in human resources, talent development, employee experience, and diversity and inclusion. As CHRO, Mr. Morton will oversee all human resources aspects of the Company
Amy Belt Raimundo to Join NuVasive Board of Directors
SAN DIEGO, Aug. 9, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the appointment of Amy Belt Raimundo to the Company's Board of Directors, effective August 9, 2021. Ms. Raimundo has more than 20 years of experience in healthcare, with extensive knowledge in medical technology, healthcare strategy, and digital health. Currently, she is the co-founder and Managing Partner for Convey Capital, a venture capital fund fo
NuVasive Appoints Daniel J. Wolterman as Independent Board Chair
SAN DIEGO, May 19, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the appointment of Daniel J. Wolterman as independent chair of the NuVasive Board of Directors, effective immediately. Mr. Wolterman succeeds Gregory T. Lucier as the Company's Board chair, following Mr. Lucier's retirement from the Board on May 18, 2021. "As a long-standing member of our Board of Directors, Dan's expertise and leadership will help NuV
NuVasive Appoints Juliet C. Cunningham as Vice President of Investor Relations
SAN DIEGO, May 10, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the appointment of Juliet C. Cunningham as the vice president of Investor Relations, effective immediately. In this role, Ms. Cunningham is responsible for the Company's investor relations program and reports directly to Chief Financial Officer Matt Harbaugh. Ms. Cunningham has more than 25 years of experience in investor relations and corporate commu
NuVasive Announces Retirement of Gregory T. Lucier from Board of Directors
SAN DIEGO, March 25, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced Gregory T. Lucier will be retiring from the NuVasive Board of Directors effective May 18, 2021. "I want to thank Greg for his leadership and guidance to NuVasive and the Board of Directors. His extensive medical device background and experience commercializing disruptive technology helped expand the Company's key growth areas and build a strong foundation for our long-term strategy," said J. Christopher Barry, chief executive officer of NuVasive. "Greg is a visio
Dr. Siddhartha Kadia to Join NuVasive Board of Directors
SAN DIEGO, Feb. 1, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the appointment of Siddhartha Kadia, Ph.D. to the Company's Board of Directors, effective February 1, 2021. Dr. Kadia has more than 20 years of experience in the medical technology industry with expertise in globally commercializing disruptive technology. He most recently served as president and CEO of EAG Laboratories, a global scientific services company providing analytical testing and consulting solutions, which was acquired by Eurofins Scientific for $780 mi
NuVasive Inc. Financials
Live finance-specific insights
NuVasive Announces Second Quarter 2023 Financial Results
–U.S. Cervical continues to deliver greater than 20% year-over-year growth––International net sales grew 6.8% as reported and 9.8% on a constant currency basis– SAN DIEGO, Aug. 2, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2023. Second Quarter 2023 Highlights Net sales were $317.8 million, a 2.4% increase as reported and a 3.1% increase on a constant currency basi
NuVasive Announces Conference Call and Webcast of Second Quarter 2023 Results
SAN DIEGO, July 24, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that it will release its second quarter 2023 results on Wednesday, August 2, 2023, after the close of the market. NuVasive will hold a conference call on Wednesday, August 2, 2023, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results of its financial performance for the second quarter of 2023. The dial-in numbers are 1-877-407-9039 for domestic calle
NuVasive Announces First Quarter 2023 Financial Results
–Continued above-market worldwide net sales growth of 5.8% as reported and 7.7% on a constant currency basis––U.S. cervical delivers sixth consecutive quarter of greater than 20% growth, driven by C360 and the Simplify Cervical Disc– SAN DIEGO, May 10, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended March 31, 2023. First Quarter 2023 Highlights Net sales were $307.7 million, a
NuVasive Announces Conference Call and Webcast of First Quarter 2023 Results
SAN DIEGO, May 4, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its first quarter 2023 results on Wednesday, May 10, 2023, after the close of the market. NuVasive will hold a conference call on Wednesday, May 10, 2023, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results of its financial performance for the first quarter of 2023. The dial-in numbers are 1-877-300-8521 for domestic callers a
NuVasive Announces Fourth Quarter and Full-Year 2022 Financial Results and 2023 Net Sales Guidance
– Full-year 2022 net sales grew 5.5% as reported, 8.5% on a constant currency basis – – Continued strong international growth in 2022 – – U.S. cervical delivers growth of greater than 20% year-over-year driven by C360 – – 2,000+ Pulse cases performed worldwide since commercial launch – SAN DIEGO, Feb. 22, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter and full year ended December 31, 2022.
Globus Medical and NuVasive to Combine in All-Stock Transaction to Create Innovative Global Musculoskeletal Company Focused on Patient Care
Capitalizes on complementary global commercial organizations and accelerates Globus Medical's and NuVasive's globalization strategies to increase customer reach and deepen surgeon relationships Brings together innovative technologies to create comprehensive procedural solutions offering to better support surgeons, healthcare providers and patients Leverages shared commitment to innovation to further both companies' efforts to address the full continuum of care and help solve unmet clinical needs Expands operational excellence capabilities to further serve and enable the combined commercial organizations to better support customers Strong financial profile and value creation opportunity Compa
NuVasive Announces Conference Call and Webcast of Fourth Quarter and Full-Year 2022 Results
SAN DIEGO, Jan. 30, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its fourth quarter and full-year 2022 results on Wednesday, February 22, 2023, after the close of the market. NuVasive will hold a conference call on Wednesday, February 22, 2023, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results of its financial performance for the fourth quarter and full year ended December 31, 2022. The
NuVasive Announces Third Quarter 2022 Financial Results
– Net sales grew 9.0% as reported, 12.9% on a constant currency basis – – C360 portfolio delivers record quarter in cervical net sales – – Company updates full-year 2022 guidance – SAN DIEGO, Nov. 9, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended September 30, 2022. Third Quarter 2022 Net sales were $295.3 million, a 9.0% increase as reported and a 12.9% increase on a constant
NuVasive Announces Conference Call and Webcast of Third Quarter 2022 Results
SAN DIEGO, Oct. 25, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its third quarter financial results on Wednesday, November 9, 2022, after the market close. NuVasive will hold a conference call on Wednesday, November 9, 2022, at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results of its financial performance for the third quarter ended September 30, 2022. The dial-in numbers are 1-877-300-85
NuVasive Announces Second Quarter 2022 Financial Results
–Strong year-over-year net sales growth, driven by new product introductions– –Company reiterates full-year guidance range for reported year-over-year net sales growth of 6%–8%– –Company updates full-year guidance range for GAAP diluted EPS; maintains prior non-GAAP diluted EPS range provided May 4, 2022– SAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2022.
NuVasive Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
SEC Form SC 13G/A filed by NuVasive Inc. (Amendment)
SC 13G/A - NUVASIVE INC (0001142596) (Subject)
SEC Form SC 13G filed by NuVasive Inc.
SC 13G - NUVASIVE INC (0001142596) (Subject)
SEC Form SC 13G/A filed by NuVasive Inc. (Amendment)
SC 13G/A - NUVASIVE INC (0001142596) (Subject)
SEC Form SC 13G/A filed by NuVasive Inc. (Amendment)
SC 13G/A - NUVASIVE INC (0001142596) (Subject)
SEC Form SC 13G filed by NuVasive Inc.
SC 13G - NUVASIVE INC (0001142596) (Subject)
SEC Form SC 13G/A filed by NuVasive Inc. (Amendment)
SC 13G/A - NUVASIVE INC (0001142596) (Subject)
SEC Form SC 13G/A filed by NuVasive Inc. (Amendment)
SC 13G/A - NUVASIVE INC (0001142596) (Subject)
SEC Form SC 13G filed by NuVasive Inc.
SC 13G - NUVASIVE INC (0001142596) (Subject)
SEC Form SC 13G/A filed by NuVasive, Inc. (Amendment)
SC 13G/A - NUVASIVE INC (0001142596) (Subject)
SEC Form SC 13G/A filed by NuVasive, Inc. (Amendment)
SC 13G/A - NUVASIVE INC (0001142596) (Subject)